Clopidogrel, a CYP2C8 inhibitor, causes a clinically...

  • Main
  • 2020 / 05
  • Clopidogrel, a CYP2C8 inhibitor, causes a clinically...

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects

Axelsen, Lene Nygaard, Poggesi, Italo, Rasschaert, Freya, Perez Ruixo, Juan Jose, Bruderer, Shirin
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
British Journal of Clinical Pharmacology
DOI:
10.1111/bcp.14365
Date:
May, 2020
File:
PDF, 1.23 MB
2020
Conversion to is in progress
Conversion to is failed